From our origins as a spin out of Nottingham University to the global organization that we are today this year marks 35 years of Quotient Sciences helping clients accelerate drug development and advance new treatments to patients. 

We are incredibly proud of our achievements and what our teams have done in this time to make a mark on improving health and wellbeing. 

From our inception, innovation, customer service, and collaboration have been a focus of the business. We’ve kept sight of how to better serve our clients by finding time-saving, cost-effective, or novel ways to help our customers reach milestones more efficiently. This has included the creation of highly integrated approaches and operational models, like our Translational Pharmaceutics® platform. 

Over the last three decades, we have worked on thousands of molecules—from cancer treatments to rare disease therapies—many of which are now positively impacting patient lives every day.

During recent presentations broadcasted from Nottingham to all colleagues globally, Dr. Ian Wilding, one of the company’s founders; Dr. Peter Scholes, former Chief Scientific Officer; and Dr. Andy Lewis, our current Chief Scientific Officer, discussed how the company started, where the company has been, its innovations, and the milestones ahead that will shape our future. Throughout the years, our team culture and collaboration have remained consistent and enabled us to deliver programs effectively for our clients. 

To recognize the company’s track record of celebrating our history and impact, we’ve compiled a list of 35 interesting facts that best illustrate the story of Quotient Sciences’ 35 years.

Our story: 

1.    We work with emerging biotech firms and Fortune 500 pharma companies. Past and present clients include all of the leading large pharma and biotech companies in the world, representing a significant portion of the global pharmaceutical industry. 
2.    All new medicines undergo rigorous testing before they can be prescribed or sold, and the clinical trials run by Quotient Sciences are part of this process. We have a deep commitment to safety and quality.
3.    We ask every customer for their feedback and we are proud to say that our average customer satisfaction score is 9 out of 10. 
4.    The company was founded in 1990 and was known as Pharmaceutical Profiles until 2009 when it changed to Quotient Bioresearch. 
5.    We first expanded to Edinburgh, adding data sciences to our portfolio of services. Co-Formulate, a UK-based CDMO, was acquired in 2015, to bring on board world leading expertise in pediatric product development.
6.    The acquisition of Reading, UK-based Pharmaterials in 2017 added expertise in inhaled drug development and scale up capability to further expand our UK footprint.
7.    2017 was a milestone year, with a rebranding to Quotient Sciences and expansion to the U.S. Quotient Sciences acquired a CRO in Miami, FL (Seaview Research), and CDMO capacity in Philadelphia (QS Pharma). 
8.    Quotient Sciences expanded to Alnwick, UK in 2021, adding drug substance, bioanalysis, and a related portfolio of services.
9.    Today, the Alnwick and Reading, UK facilities are part of Arcinova, which relaunched in 2025 to focus on early-stage drug development.

Our facilities & capabilities: 

10.    Collectively Quotient Sciences and Arcinova operate from 7 locations in the US and UK.
11.    Our Philadelphia operations include two distinct facilities: Boothwyn and Garnet Valley. There are plans for a third facility to open in Garnet Valley in the future.
12.    Eight FDA-approved therapies, including a pediatric cancer treatment, are currently produced in Philadelphia at our commercial product manufacturing site.
13.    In 2020, we expanded our in-house compounding pharmacy in Miami, Fl, to support faster paths to FIH trials.
14.    Our facility in Boothwyn, Pa. (Chelsea Parkway) was upgraded in 2025 for safer handling of HPAPI products, protecting our teams and adding capacity while ensuring we remain a drug product manufacturing partner of choice for our clients.
15.    Our facility in Nottingham houses one of UK/EU’s largest and most experienced clinical pharmacology units and 6 co-located GMP rooms. 
16.    Between Miami and Nottingham, we have a total of 230 beds dedicated to early phase clinical trials in healthy volunteers and certain patient groups. 
17.    To date, our longest continuous clinical trial was in Miami, where a group of volunteers stayed for 60 consecutive days with us on-site as a single residency. In Nottingham, our longest continuous trial was 42 days.
18.    In Miami, our longest clinical study duration was 1009 days (almost 3 years!)

Our innovations over the years:

19.    Translational Pharmaceutics® is the company’s unique drug development platform. A comprehensive approach to formulation development, on-demand GMP manufacturing, and clinical testing that enables better outcomes for our clients.
20.    Translational Pharmaceutics® was introduced nearly two decades ago and we’ve completed over 500 programs to date between our sites in the UK and US. 
21.    Our approach to project management is key in ensuring timely and budget-compliant delivery of drug development projects while maintaining high standards of quality and compliance, facilitating a smooth and efficient process from concept to final product.
22.    The company was recognized recently with a Fierce CRO Award for innovation in drug development in 2024, and 2023 Pharma Innovation Award (Pharma Manufacturing).
23.    We recently announced a partnership with UK-based CPI (Centre for Process Innovation) to improve mRNA therapy development, with the aim of bringing new treatments to patients faster by improving the pathways between manufacturing and clinical testing. 
24.    Our first Scientific Advisory Board was established earlier in 2025. The board will provide input on research and development priorities, technology investments, and scientific strategy.  
25.    Quotient Sciences is actively exploring AI to accelerate drug formulation and development processes.
26.    In 2023, we presented over 25 posters along with having 5 speaking engagements at conferences and 4 papers in peer-reviewed journals. This momentum has continued. One highlight for 2025 was a co-authored paper with YourChoice Therapeutics published in Communications Medicine, a Nature Portfolio Journal, detailing the results of their Phase I study on a new, non-hormonal male birth control. 

Our commitments to ESG, our colleagues & our future:

27.    More than 1,100 talented colleagues work across the US, UK and parts of Europe to support a global mission: bringing molecules to cures, fast, for those in need.
28.    Science, agility, and culture are the three pillars that define who we are and fuel our success. 
29.    ESG is central to how we operate. Our inaugural ESG report showed a 23% improvement in our EcoVadis sustainability score in 2023, and we proudly sustained that score in 2024—demonstrating our long-term dedication to sustainability.
30.    100% of our electricity usage in the UK was from renewable energy sources in 2024, and we purchased multiple renewable energy certificates (REC) in the US.
31.    By signing the UN Global Compact, we’ve reinforced our commitment to ethical, transparent, and responsible business practices on a global scale.
32.    Many of our new team members say they’ve found friendly, welcoming, and collaborative colleagues from day one, helping them feel part of something bigger.
33.    We’re incredibly proud to have so many long-serving colleagues at Quotient Sciences, with 20+ years of service in some cases! They’ve witnessed first-hand the journey that’s shaped who we are today.
34.    Quotient Sciences colleagues are always learning, evolving, and pushing boundaries to advance science and accelerate drug development. 
35.    Our colleagues are passionate about making a difference—knowing their work contributes to meaningful therapies that help patients around the world.

As the pharmaceutical landscape evolves, Quotient Sciences remains committed to its mission: bringing molecules to cures, fast. We continue to push boundaries with initiatives in artificial intelligence and mRNA therapy development, including a recently-announced joint venture with CPI. 

“Every molecule we work on represents the potential to transform lives,” says CEO Thierry Van Nieuwenhove. “Our culture of collaboration, agility, and scientific excellence drives us to deliver on that promise.”
 

Thierry Van Nieuwenhove, CEO of Quotient Sciences, contributes to Business Reporter and Independent's piece on Quotient Sciences, 'Fortifying Pharmaceutical Innovation, from Laboratory to Clinic'.

With a global client base ranging from emerging biotechnology organizations to Fortune 500 pharmaceutical companies, Quotient Sciences offers a compelling solution for innovators seeking speed, efficiency and quality in bringing new therapies to patients.

For 35 years and with operations in the UK and the US, Quotient Sciences has worked on hundreds of products used to treat conditions ranging from cancer to rare diseases. As a contract research, development and manufacturing organization (CRDMO), the company specializes in the early clinical research and development of drug products for clinical trials and prescription medicines.

Thierry Van Nieuwenhove states, “When clients work with us, they access a team that has collectively worked on thousands of new molecules. Experts from different functions are brought together for every project. We consistently hear from clients how much they appreciate input from such a diverse team to advance programs and make more informed decisions.”

Quotient Sciences’ commitment to innovation makes it a vital partner in translating the UK’s scientific excellence into real-world health and economic impact, especially as the sector continues to embrace digital transformation and new applications of artificial intelligence.

Van Nieuwenhove says, “Every project is driven by the knowledge that behind each molecule lies the potential to transform health. Our culture is built on collaboration, learning, science and agility. These are core to meet our mission of bringing molecules to cures, fast.” 

Read the full article on the Business Reporter website here or on the Independent website here.

Summary: Emily Dodds works as a Research Fellow within Quotient Sciences’ Scientific Consulting team in Nottingham, UK. She discusses her career with the company and what she enjoys most about her role. 

Get to know the people behind Quotient Sciences in our colleague Q&A series. 

What does a Research Fellow do at Quotient Sciences? 

As Research Fellows, we contribute to early study discussions by helping design and review clinical pharmacology and Translational Pharmaceutics® studies. We also provide scientific oversight by acting as Science Leads, supporting internal teams throughout the operational phases to ensure scientific integrity and alignment with study objectives.

Describe a typical day in Scientific Consulting. 

My day varies depending on the stage of each project. It can include designing studies, generating a synopsis, reviewing protocols and study reports, and attending key meetings such as weekly client calls, dose decisions, and new sponsor discussions.

How has your career progressed since joining us? 

I began as an Associate Formulation Scientist during my university placement, where I also shadowed the Research Fellow role for industrial exposure. After graduating, I was offered a 6-month secondment in the Scientific Consulting department, which evolved into a permanent position. I’ve now been in the team for over 3.5 years, continuing to grow and contribute as a Research Fellow.

What experience did you have before you worked at Quotient Sciences? 

Before joining Quotient Sciences, my experience was limited to part-time roles. My placement year as a Formulation Scientist was my first full-time industry position, which gave me invaluable exposure to pharmaceutical development and helped build the connections that led to my return post-graduation.

Did you require any qualifications for the role you applied for? 

Prior to starting the role, I had a BSc in Pharmacology which provided a solid foundation in drug development and pharmacokinetics. While many aspects of the role are learned on the job, a background in biosciences and any prior clinical or industry experience are definitely advantageous.

What learning or qualifications have you gained in this role? 

This role has significantly developed my skills in clinical study design and the scientific considerations involved. I also had the opportunity to complete an MSc in Clinical Pharmacology, which deepened my expertise and enhanced my contributions to the team.

What do you enjoy most about your role? 

I enjoy the variety of tasks and the dynamic nature of the work, which keeps things interesting and allows me to continuously learn and grow.

What aspects do you find most challenging? 

Managing time effectively across multiple studies can be challenging. It’s important to stay organized and adaptable to ensure each project receives the support it needs.

What’s the team like? 

Although the Research Fellow group is small, the wider Scientific Consulting department is incredibly collaborative and inspiring. Being part of a team that engages in diverse scientific discussions and innovations makes the work environment interesting and supportive.

What advice would you give to someone applying for a role in your team? 

Highlight your key skills and any experience in clinical trials or drug development. Be clear about your motivations for applying and show enthusiasm for contributing to a collaborative scientific environment.

What do you like most about working at Quotient Sciences? 

The people and the cross-functional collaboration make Quotient Sciences a great place to work. There’s a strong sense of community and shared purpose that makes the work both enjoyable and meaningful.

“The people and the cross-functional collaboration make Quotient Sciences a great place to work. There’s a strong sense of community and shared purpose that makes the work both enjoyable and meaningful.” 

– Emily Dodds

Quotient Sciences Featured in Contract Pharma's feature on HPAPI Outsourcing

Senior Director of Product Development, Robert Cornog, and Senior Director of Integrated Development, Brad Rowe, recently contributed to Contract Pharma's feature on HPAPI outsourcing, "Why HPAPI Outsourcing Is Surging", explaining the evolving demand, regulatory shifts, and analytical challenges shaping the HPAPI contract manufacturing market.

When speaking on regulatory pressures, Robert Cornog states, "Recent regulatory focus on workers' safety and risk-based applications to cross-contamination has been driving the increasing need for isolation controls and validated operations, particularly for multi-product facilities. These considerations are being pushed earlier and earlier into the conceptual and design phases for equipment and facilities."

When addressing analytical challenges, Brad Rowe explains, "The manufacturing of HPAPI drug products requires the demonstration of very low acceptable levels of residual compound on the manufacturing equipment, which can pose challenges in cleaning verification analysis and their quantification limits. Likewise, HPAPI drug products tend to be on the very low end of product strengths, again making assay, and in particular related substances analysis, challenging to achieve the appropriate levels of quantitation limits."

When asked how CDMOs are addressing these challenges, Rowe says, "Methodology that targets the analysis of specific compounds, such as HPLC-Mass Spectrometry, can help overcome these challenges with improved quantitative abilities."

To continue reading the full article, visit Contract Pharma's site here.